Testosterone Therapy May Benefit Hypogonadal CP/CPSS Sufferers
Patients experienced significant improvements in symptoms and quality of life parameters.
NEW ORLEANS—Testosterone replacement therapy (TRT) may be an effective treatment for hypogonadism in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), according to data presented at the 2015 American Urological Association annual meeting.
In a prospective study conducted by Ran Pang, MD, and colleagues at the China Academy of Chinese Medical Sciences in Beijing, China, TRT improved clinical symptoms, quality of life (QOL), and psychological status.
The 48 patients enrolled in the study received testosterone undecanoate 80 mg orally twice daily for 12 weeks. Of the 48 patients, 45 completed 12 weeks of follow-up. Subjects had a mean age of 47 years and CP/CPPS duration of 1–7 years.
At the end of treatment, patients' total NIH Chronic Prostatitis Symptoms Index (NIH-CPSI) mean score decreased significantly from 22 at baseline to 11.2 post-treatment. Mean scores on the pain and QOL domains of the NIH-CPSI and scores decreased significantly (from 11.9 to 5.3 and from 7.8 to 3.8, respectively), as did scores on the Hamilton Anxiety Scale and Hamilton Depression Scale (from 19.7 to 8.3 and from 16.9 to 10.1, respectively).
Serum total testosterone levels rose from 257.8 to 386.1 ng/dL.
In a separate study presented at the meeting, Young Lee, MD, of Kyung Hee University College of Medicine in Seoul, South Korea, and colleagues reported on a study of 9,180 middle-aged men (mean age 52.3 years) showing that late-onset hypogonadism (LOH) was significantly correlated with the presence and severity of prostatitis-like symptoms as assessed using the NIH-CPSI. The study demonstrated a significant increase in the incidence of LOH as the severity of prostatitis-like symptoms increased.